insulin and glp-1 agonist combination Fixed Ratio Overview - Combination Basal + GLP-1RA Therapy Frontiers | GLP-1 Receptor Agonists:

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

Algorithm for Adding/Intensifying Prandial Control

See how GLP-1s are reshaping diabetes & obesity care.

A new era for weight loss

Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities.

Learn key patient education tips for GLP-1 care management, the importance of multidisciplinary care teams and how remote care providers fit into the equation.